Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,957 shares of the biopharmaceutical company's stock after purchasing an additional 1,346 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Alnylam Pharmaceuticals were worth $3,499,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its position in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the period. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $28,000. Whipplewood Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Finally, OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $35,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on ALNY shares. HC Wainwright restated a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Royal Bank Of Canada boosted their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Finally, Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Monday, June 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-one have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $340.00.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at $14,899,281.72. This represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY traded up $2.17 during trading hours on Friday, hitting $331.94. 431,157 shares of the stock were exchanged, compared to its average volume of 853,986. The company has a market cap of $43.28 billion, a price-to-earnings ratio of -158.82 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $333.70. The stock has a 50-day moving average of $294.96 and a 200 day moving average of $266.07. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same period in the prior year, the company earned ($0.16) earnings per share. The company's revenue for the quarter was up 20.2% on a year-over-year basis. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.